Free Trial

ACADIA Pharmaceuticals (ACAD) Competitors

ACADIA Pharmaceuticals logo
$21.02 +0.14 (+0.67%)
Closing price 04:00 PM Eastern
Extended Trading
$21.02 +0.00 (+0.02%)
As of 06:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ACAD vs. ITCI, GMAB, RDY, QGEN, MRNA, ASND, VTRS, BPMC, BBIO, and VRNA

Should you be buying ACADIA Pharmaceuticals stock or one of its competitors? The main competitors of ACADIA Pharmaceuticals include Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), Moderna (MRNA), Ascendis Pharma A/S (ASND), Viatris (VTRS), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), and Verona Pharma PLC American Depositary Share (VRNA). These companies are all part of the "pharmaceutical products" industry.

ACADIA Pharmaceuticals vs. Its Competitors

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Intra-Cellular Therapies (NASDAQ:ITCI) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

ACADIA Pharmaceuticals has a net margin of 22.97% compared to Intra-Cellular Therapies' net margin of -14.07%. ACADIA Pharmaceuticals' return on equity of 17.46% beat Intra-Cellular Therapies' return on equity.

Company Net Margins Return on Equity Return on Assets
ACADIA Pharmaceuticals22.97% 17.46% 10.75%
Intra-Cellular Therapies -14.07%-9.93%-8.38%

ACADIA Pharmaceuticals currently has a consensus price target of $27.88, indicating a potential upside of 32.61%. Intra-Cellular Therapies has a consensus price target of $109.70, indicating a potential downside of 16.81%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe ACADIA Pharmaceuticals is more favorable than Intra-Cellular Therapies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ACADIA Pharmaceuticals
0 Sell rating(s)
6 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.71
Intra-Cellular Therapies
0 Sell rating(s)
10 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.17

In the previous week, ACADIA Pharmaceuticals had 5 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 6 mentions for ACADIA Pharmaceuticals and 1 mentions for Intra-Cellular Therapies. ACADIA Pharmaceuticals' average media sentiment score of 0.78 beat Intra-Cellular Therapies' score of 0.00 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ACADIA Pharmaceuticals
3 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Intra-Cellular Therapies
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.3% of Intra-Cellular Therapies shares are owned by institutional investors. 28.3% of ACADIA Pharmaceuticals shares are owned by insiders. Comparatively, 2.6% of Intra-Cellular Therapies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

ACADIA Pharmaceuticals has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500.

ACADIA Pharmaceuticals has higher revenue and earnings than Intra-Cellular Therapies. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ACADIA Pharmaceuticals$957.80M3.67$226.45M$1.3715.34
Intra-Cellular Therapies$680.50M20.64-$139.67M-$0.73-180.64

Summary

ACADIA Pharmaceuticals beats Intra-Cellular Therapies on 15 of the 17 factors compared between the two stocks.

Get ACADIA Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACAD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ACAD vs. The Competition

MetricACADIA PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$3.49B$2.88B$5.47B$8.95B
Dividend YieldN/A2.46%5.25%4.06%
P/E Ratio15.347.5719.7120.50
Price / Sales3.67286.98435.75120.29
Price / Cash29.6241.1936.8257.86
Price / Book4.787.487.985.56
Net Income$226.45M-$55.04M$3.16B$248.40M
7 Day Performance-1.59%5.44%3.69%6.04%
1 Month Performance-4.37%2.38%2.91%7.69%
1 Year Performance28.80%5.53%34.30%20.97%

ACADIA Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ACAD
ACADIA Pharmaceuticals
4.6786 of 5 stars
$21.02
+0.7%
$27.88
+32.6%
+29.4%$3.49B$957.80M15.34510
ITCI
Intra-Cellular Therapies
0.7394 of 5 stars
$131.87
flat
$109.70
-16.8%
N/A$14.05B$680.50M-151.57560News Coverage
GMAB
Genmab A/S
4.0118 of 5 stars
$20.66
+0.8%
$37.60
+82.0%
-19.7%$13.25B$3.12B11.742,682Positive News
Analyst Forecast
RDY
Dr. Reddy's Laboratories
2.7038 of 5 stars
$15.03
-0.3%
$16.95
+12.8%
-3.4%$12.55B$3.81B22.7727,811
QGEN
Qiagen
3.8869 of 5 stars
$48.07
+0.6%
$49.40
+2.8%
+18.8%$10.69B$1.98B120.525,765Dividend Announcement
MRNA
Moderna
4.3806 of 5 stars
$27.59
+1.6%
$46.61
+68.9%
-74.7%$10.67B$3.24B-3.165,800
ASND
Ascendis Pharma A/S
3.6014 of 5 stars
$172.60
+0.2%
$220.67
+27.8%
+29.6%$10.55B$393.54M-27.481,017Positive News
VTRS
Viatris
2.6626 of 5 stars
$8.93
-0.9%
$10.40
+16.5%
-10.9%$10.48B$14.74B-2.8232,000
BPMC
Blueprint Medicines
1.516 of 5 stars
$128.18
+0.1%
$128.06
-0.1%
+15.0%$8.28B$562.12M-51.89640Insider Trade
BBIO
BridgeBio Pharma
4.6636 of 5 stars
$43.18
-3.7%
$58.85
+36.3%
+68.9%$8.20B$221.90M-12.23400High Trading Volume
VRNA
Verona Pharma PLC American Depositary Share
2.6162 of 5 stars
$94.58
+0.8%
$101.10
+6.9%
+466.1%$8.05B$42.28M-47.2930Positive News

Related Companies and Tools


This page (NASDAQ:ACAD) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners